A proposal to incorporate trial data into a hybrid ACC/AHA algorithm for the allocation of statin therapy in primary prevention.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Journal of the American College of Cardiology

• Publication date

  2015-03-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jacc.2014.12.028PMID 25744012
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Do current clinical trials meet society's needs?: a critical review of recent evidence.

  2014cited by this paper
• Further insight into the cardiovascular risk calculator: the roles of statins, revascularizations, and underascertainment in the Women's Health Study.

  2014cited by this paper
• Personalized cardiovascular disease prevention by applying individualized prediction of treatment effects.

  2014cited by this paper
• 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

  2014cited by this paper
• 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

  2014cited by this paper
• LDL cholesterol: controversies and future therapeutic directions.

  2014cited by this paper
• 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

  2014cited by this paper
• Faculty Opinions recommendation of 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

  2014cited by this paper
• Statins: new American guidelines for prevention of cardiovascular disease.

  2013cited by this paper
• A trial-based approach to statin guidelines.

  2013cited by this paper
• What works and in whom? A simple, easily applied, evidence-based approach to guidelines for statin therapy.

  2012cited by this paper
• Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial.

  2012cited by this paper
• The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials

  2012cited by this paper
• Screening for Future Cardiovascular Disease Using Age Alone Compared with Multiple Risk Factors and Age

  2011cited by this paper
• Estimating treatment effects for individual patients based on the results of randomised clinical trials

  2011cited by this paper
• Balancing the benefits of statins versus a new risk-diabetes.

  2010cited by this paper
• Rosuvastatin in older patients with systolic heart failure.

  2009cited by this paper
• Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.

  2009cited by this paper
• Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.

  2008cited by this paper
• Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial.

  2008cited by this paper
• Rosuvastatin in older patients with systolic heart failure.

  2007cited by this paper
• Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial.

  2006cited by this paper
• Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.

  2005cited by this paper
• National Center for Health Statistics (NCHS)

  2005cited by this paper
• Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

  2004cited by this paper
• PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA

  2000cited by this paper
• Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

  1998cited by this paper
• Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

  1995cited by this paper

• Recommendations for statin management in primary prevention: disparities among international risk scores

  2023influential citation
• Comment on: LDL-C – when to calculate and when to measure?

  2023cites this paper
• The Role of Coronary Artery Calcium Testing for Value-Based Clinical Trials in Primary Prevention

  2021cites this paper
• Projections of incident atherosclerotic cardiovascular disease and incident type 2 diabetes across evolving statin treatment guidelines and recommendations: A modelling study

  2020cites this paper
• Cholesterol Lowering Guidelines: From Whence We Came and Where We Are Now.

  2019cites this paper
• Can We Eliminate Low-Density Lipoprotein Cholesterol-Related Cardiovascular Events Through More Aggressive Primary Prevention Therapy?

  2018cites this paper
• Managing dyslipidaemia for the primary prevention of cardiovascular disease

  2018cites this paper
• Comentario editorial: Prevención primaria con estatinas en mayores de 65 años ¿decisiones basadas en ecuaciones de riesgo, medicina basada en evidencia o tratamiento centrado en el paciente?

  2018cites this paper
• Fenofibrate modified-release pellets with lag phase and high oral bioavailability

  2018cites this paper
• Selecting Patients for Statin Therapy in Primary Prevention If We Could Only Predict the Future*

  2017cites this paper
• Statin Trials, Cardiovascular Events, and Coronary Artery Calcification: Implications for a Trial-Based Approach to Statin Therapy in MESA.

  2017cites this paper
• What Is the Best Disease-Guided Approach to Statin?

  2017cites this paper
• Assessing gaps in cholesterol treatment guidelines for primary prevention of cardiovascular disease based on available randomised clinical trial evidence: The Rotterdam Study

  2017cites this paper
• Comparison of ACC/AHA and ESC Guideline Recommendations Following Trial Evidence for Statin Use in Primary Prevention of Cardiovascular Disease: Results From the Population-Based Rotterdam Study.

  2016cites this paper
• Identifying Persons at Increased Risk of Cardiovascular Disease

  2016cites this paper
• Statins for primary prevention

  2016cites this paper
• Individualized Statin Benefit for Determining Statin Eligibility in the Primary Prevention of Cardiovascular Disease

  2016cites this paper
• Advances in the treatment of dyslipidemia

  2016cites this paper
• Recent Update to the US Cholesterol Treatment Guidelines: A Comparison With International Guidelines.

  2016cites this paper
• Statin Therapy as Primary Prevention in Exercising Adults: Best Evidence for Avoiding Myalgia

  2016cites this paper
• «НЕПОТЕРЯННОЕ ВРЕМЯ» В ПРОФИЛАКТИКЕ РАЗВИТИЯ ОСЛОЖНЕНИЙ СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЙ: ОТДАЛЕННЫЕ РЕЗУЛЬТАТЫ ПРИМЕНЕНИЯ СТАТИНОВ С ЦЕЛЬЮ ПЕРВИЧНОЙ ПРОФИЛАКТИКИ

  2016cites this paper
• Should we reconsider the role of age in treatment allocation for primary prevention of cardiovascular disease?

  2016cites this paper
• Refining Statin Prescribing in Lower-Risk Individuals: Informing Risk/Benefit Decisions.

  2016cites this paper
• Selecting Patients for Statin Therapy in Primary Prevention: If We Could Only Predict the Future.

  2015cites this paper
• Primary Prevention With Statins: ACC/AHA Risk-Based Approach Versus Trial-Based Approaches to Guide Statin Therapy.

  2015influential citation
• A Proposal to Incorporate Trial Data Into a Hybrid American College of Cardiology/American Heart Association Algorithm for the Allocation of Statin Therapy in Primary Prevention.

  2015influential citation
• Is the Best Disease-Guided

  year unknowncites this paper